Identification and characterization of the hypoxia-responsive element in human stanniocalcin-1 gene

Molecular and Cellular Endocrinology

Volumn 314, Issue 1, 2010, Pages 118-127

  Law, A Y S ^a   Ching, L Y ^a   Lai, K P ^a   Wong, Chris K C ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

FIH; p300; Promoter; siRNA

Indexed keywords

HYPOCALCIN; HYPOXIA INDUCIBLE FACTOR 1; LUCIFERASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN P300; TUMOR MARKER;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE ACTIVATION; GENE CONSTRUCT; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE STRUCTURE; HUMAN; HUMAN CELL; NASOPHARYNX CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN MOTIF; PROTEIN STABILITY; TRANSACTIVATION;

BASE SEQUENCE; CELL HYPOXIA; CELL LINE, TUMOR; GLYCOPROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; P300-CBP TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; RESPONSE ELEMENTS; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION;

EID: 70350182250     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.07.007     Document Type: Article

References (67)

1. Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C., Goldberg M.A., Bunn H.F., and Livingston D.M. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 12969-12973
2. Bell S.E., Mavila A., Salazar R., Bayless K.J., Kanagala S., Maxwell S.A., and Davis G.E. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J. Cell Sci. 114 (2001) 2755-2773
3. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 22 (2003) 4082-4090
4. Block G.J., Ohkouchi S., Fung F., Frenkel J., Gregory C., Pochampally R., Dimattia G., Sullivan D.E., and Prockop D.J. Multipotent stromal cells (MSCs) are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1 (STC-1). Stem Cells (2008)
5. Chang A.C., Janosi J., Hulsbeek M., de Jong D., Jeffrey K.J., Noble J.R., and Reddel R.R. A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol. Cell Endocrinol. 112 (1995) 241-247
6. Chang A.C., Jellinek D.A., and Reddel R.R. Mammalian stanniocalcins and cancer. Endocr. Relat. Cancer 10 (2003) 359-373
7. Cummins E.P., and Taylor C.T. Hypoxia-responsive transcription factors. Pflugers Arch. 450 (2005) 363-371
8. Dames S.A., Martinez-Yamout M., De Guzman R.N., Dyson H.J., and Wright P.E. Structural basis for Hif-1 alpha/CBP recognition in the cellular hypoxic response. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 5271-5276
9. Dayan F., Roux D., Brahimi-Horn M.C., Pouyssegur J., and Mazure N.M. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res. 66 (2006) 3688-3698
10. De Niu P., Radman D.P., Jaworski E.M., Deol H., Gentz R., Su J., Olsen H.S., and Wagner G.F. Development of a human stanniocalcin radioimmunoassay: serum and tissue hormone levels and pharmacokinetics in the rat. Mol. Cell Endocrinol. 162 (2000) 131-144
11. Deol H.K., Varghese R., Wagner G.F., and DiMattia G.E. Dynamic regulation of mouse ovarian stanniocalcin expression during gestation and lactation. Endocrinology 141 (2000) 3412-3421
12. Eisenhofer G., Huynh T.T., Pacak K., Brouwers F.M., Walther M.M., Linehan W.M., Munson P.J., Mannelli M., Goldstein D.S., and Elkahloun A.G. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr. Relat. Cancer 11 (2004) 897-911
13. Findeisen P., Rockel M., Nees M., Roder C., Kienle P., Von Knebel D.M., Kalthoff H., and Neumaier M. Systematic identification and validation of candidate genes for detection of circulating tumor cells in peripheral blood specimens of colorectal cancer patients. Int. J. Oncol. 33 (2008) 1001-1010
14. Fujiwara Y., Sugita Y., Nakamori S., Miyamoto A., Shiozaki K., Nagano H., Sakon M., and Monden M. Assessment of stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers. Int. J. Oncol. 16 (2000) 799-804
15. Gerritsen M.E., and Wagner G.F. Stanniocalcin: no longer just a fish tale. Vitam. Horm. 70 (2005) 105-135
16. Gerritsen M.E., Soriano R., Yang S., Ingle G., Zlot C., Toy K., Winer J., Draksharapu A., Peale F., Wu T.D., and Williams P.M. In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. Physiol. Genom. 10 (2002) 13-20
17. Ghosh A.K., and Varga J. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J. Cell Physiol. 213 (2007) 663-671
18. Gogvadze V., Orrenius S., and Zhivotovsky B. Mitochondria in cancer cells: what is so special about them?. Trends Cell Biol. 18 (2008) 165-173
19. Hammond E.M., and Giaccia A.J. Hypoxia-inducible factor-1 and p53: friends, acquaintances, or strangers?. Clin. Cancer Res. 12 (2006) 5007-5009
20. Ishibashi K., and Imai M. Prospect of a stanniocalcin endocrine/paracrine system in mammals. Am. J. Physiol. Renal Physiol. 282 (2002) F367-F375
21. Ismail R.S., Baldwin R.L., Fang J., Browning D., Karlan B.Y., Gasson J.C., and Chang D.D. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 60 (2000) 6744-6749
22. Kahn J., Mehraban F., Ingle G., Xin X., Bryant J.E., Vehar G., Schoenfeld J., Grimaldi C.J., Peale F., Draksharapu A., Lewin D.A., and Gerritsen M.E. Gene expression profiling in an in vitro model of angiogenesis. Am. J. Pathol. 156 (2000) 1887-1900
23. Koivunen P., Hirsila M., Gunzler V., Kivirikko K.I., and Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 279 (2004) 9899-9904
24. Koong A.C., Chen E.Y., and Giaccia A.J. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res. 54 (1994) 1425-1430
25. Kung A.L., Zabludoff S.D., France D.S., Freedman S.J., Tanner E.A., Vieira A., Cornell-Kennon S., Lee J., Wang B., Wang J., Memmert K., Naegeli H.U., Petersen F., Eck M.J., Bair K.W., Wood A.W., and Livingston D.M. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 (2004) 33-43
26. Lai K.P., Law A.Y., Yeung H.Y., Lee L.S., Wagner G.F., and Wong C.K. Induction of stanniocalcin-1 expression in apoptotic human nasopharyngeal cancer cells by p53. Biochem. Biophys. Res. Commun. 356 (2007) 968-975
27. Lal A., Peters H., St Croix B., Haroon Z.A., Dewhirst M.W., Strausberg R.L., Kaanders J.H., van der Kogel A.J., and Riggins G.J. Transcriptional response to hypoxia in human tumors. J. Natl. Cancer Inst. 93 (2001) 1337-1343
28. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., and Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16 (2002) 1466-1471
29. Lando D., Peet D.J., Whelan D.A., Gorman J.J., and Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295 (2002) 858-861
30. Law A.Y., Lai K.P., Ip C.K., Wong A.S., Wagner G.F., and Wong C.K. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Exp. Cell Res. 314 (2008) 1823-1830
31. Law A.Y., Lai K.P., Lui W.C., Wan H.T., and Wong C.K. Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation. Exp. Cell Res. 314 (2008) 2975-2984
32. Liang S.X., and Richardson D.R. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis 24 (2003) 1601-1614
33. Lisy K., and Peet D.J. Turn me on: regulating HIF transcriptional activity. Cell Death. Differ. 15 (2008) 642-649
34. Liu D., Jia H., Holmes D.I., Stannard A., and Zachary I. Vascular endothelial growth factor-regulated gene expression in endothelial cells: KDR-mediated induction of Egr3 and the related nuclear receptors Nur77, Nurr1, and Nor1. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 2002-2007
35. Mahon P.C., Hirota K., and Semenza G.L. FIH-1, a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15 (2001) 2675-2686
36. Manalo D.J., Rowan A., Lavoie T., Natarajan L., Kelly B.D., Ye S.Q., Garcia J.G., and Semenza G.L. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105 (2005) 659-669
37. Matsui H., Ihara Y., Fujio Y., Kunisada K., Akira S., Kishimoto T., and Yamauchi-Takihara K. Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-kappa B and NF-IL6 in cardiac myocytes. Cardiovasc. Res. 42 (1999) 104-112
38. Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Activation of the HIF pathway in cancer. Curr. Opin. Genet. Dev. 11 (2001) 293-299
39. McCudden C.R., James K.A., Hasilo C., and Wagner G.F. Characterization of mammalian stanniocalcin receptors. Mitochondrial targeting of ligand and receptor for regulation of cellular metabolism. J. Biol. Chem. 277 (2002) 45249-45258
40. McCudden C.R., Majewski A., Chakrabarti S., and Wagner G.F. Co-localization of stanniocalcin-1 ligand and receptor in human breast carcinomas. Mol. Cell Endocrinol. 213 (2004) 167-172
41. Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., and Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 (2003) 751-763
42. Nguyen A., Chang A.C., and Reddel R.R. Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1/2 signaling pathway during oxidative stress. Oncogene 28 (2009) 1982-1992
43. Okabe H., Satoh S., Kato T., Kitahara O., Yanagawa R., Yamaoka Y., Tsunoda T., Furukawa Y., and Nakamura Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 61 (2001) 2129-2137
44. Olsen H.S., Cepeda M.A., Zhang Q.Q., Rosen C.A., and Vozzolo B.L. Human stanniocalcin: a possible hormonal regulator of mineral metabolism. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 1792-1796
45. Paulitschke V., Kunstfeld R., Mohr T., Slany A., Micksche M., Drach J., Zielinski C., Pehamberger H., and Gerner C. Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. J. Proteome. Res. (2009)
46. Piret J.P., Mottet D., Raes M., and Michiels C. Is HIF-1alpha a pro- or an anti-apoptotic protein?. Biochem. Pharmacol. 64 (2002) 889-892
47. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447 (2007) 425-432
48. Royds J.A., Dower S.K., Qwarnstrom E.E., and Lewis C.E. Response of tumour cells to hypoxia: role of p53 and NFkB. Mol. Pathol. 51 (1998) 55-61
49. Schmedtje Jr. J.F., Ji Y.S., Liu W.L., DuBois R.N., and Runge M.S. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 272 (1997) 601-608
50. Stasko S.E., DiMattia G.E., and Wagner G.F. Dynamic changes in stanniocalcin gene expression in the mouse uterus during early implantation. Mol. Cell Endocrinol. 174 (2001) 145-149
51. Stasko S.E., and Wagner G.F. Possible roles for stanniocalcin during early skeletal patterning and joint formation in the mouse. J. Endocrinol. 171 (2001) 237-248
52. Stasko S.E., and Wagner G.F. Stanniocalcin gene expression during mouse urogenital development: a possible role in mesenchymal-epithelial signalling. Dev. Dyn. 220 (2001) 49-59
53. To K.K., and Huang L.E. Suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) transcriptional activity by the HIF prolyl hydroxylase EGLN1. J. Biol. Chem. 280 (2005) 38102-38107
54. Varghese R., Gagliardi A.D., Bialek P.E., Yee S.P., Wagner G.F., and DiMattia G.E. Overexpression of human stanniocalcin affects growth and reproduction in transgenic mice. Endocrinology 143 (2002) 868-876
55. Varghese R., Wong C.K., Deol H., Wagner G.F., and DiMattia G.E. Comparative analysis of mammalian stanniocalcin genes. Endocrinology 139 (1998) 4714-4725
56. Wagner G.F., and DiMattia G.E. The stanniocalcin family of proteins. J. Exp. Zool. A: Comp. Exp. Biol. 305 (2006) 769-780
57. Wary K.K., Thakker G.D., Humtsoe J.O., and Yang J. Analysis of VEGF-responsive genes involved in the activation of endothelial cells. Mol. Cancer 2 (2003) 25
58. Wascher R.A., Huynh K.T., Giuliano A.E., Hansen N.M., Singer F.R., Elashoff D., and Hoon D.S. Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer. Clin. Cancer Res. 9 (2003) 1427-1435
59. Watanabe T., Ichihara M., Hashimoto M., Shimono K., Shimoyama Y., Nagasaka T., Murakumo Y., Murakami H., Sugiura H., Iwata H., Ishiguro N., and Takahashi M. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. Am. J. Pathol. 161 (2002) 249-256
60. Welcsh P.L., Lee M.K., Gonzalez-Hernandez R.M., Black D.J., Mahadevappa M., Swisher E.M., Warrington J.A., and King M.C. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 7560-7565
61. Wenger R.H., Stiehl D.P., and Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci. STKE (2005) re12
62. Westberg J.A., Serlachius M., Lankila P., and Andersson L.C. Hypoxic preconditioning induces elevated expression of stanniocalcin-1 in the heart. Am. J. Physiol. Heart Circ. Physiol. (2007)
63. Westberg J.A., Serlachius M., Lankila P., Penkowa M., Hidalgo J., and Andersson L.C. Hypoxic preconditioning induces neuroprotective stanniocalcin-1 in brain via IL-6 signaling. Stroke 38 (2007) 1025-1030
64. Wu S., Yoshiko Y., and De Luca F. Stanniocalcin 1 acts as a paracrine regulator of growth plate chondrogenesis. J. Biol. Chem. 281 (2006) 5120-5127
65. Yeung H.Y., Lai K.P., Chan H.Y., Mak N.K., Wagner G.F., and Wong C.K. Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. Endocrinology 146 (2005) 4951-4960
66. Zhang K.Z., Westberg J.A., Paetau A., von Boguslawsky K., Lindsberg P., Erlander M., Guo H., Su J., Olsen H.S., and Andersson L.C. High expression of stanniocalcin in differentiated brain neurons. Am. J. Pathol. 153 (1998) 439-445
67. Zhang K., Lindsberg P.J., Tatlisumak T., Kaste M., Olsen H.S., and Andersson L.C. Stanniocalcin: a molecular guard of neurons during cerebral ischemia. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 3637-3642